Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

World’s First Dual IVDR-Certified One-Step Strep A Rapid Test by GenSure Biotech Sets New Benchmark for Rapid Respiratory Infection Diagnostics

An innovative Group A Streptococcus “One-Step Antigen Extraction + Detection” Kit (immunochromatography), developed by GenSure Biotech Inc., has successfully obtained both Class B and Class C EU…

News • Quantitative analysis of the mammary ductal tree

Calculating breast health with branching math

Researchers have developed a tool to quickly quantify changes in the branches of mouse mammary glands. This could one day be used to detect early warning signs of breast cancer.

News • Focus on methylation changes

Detecting tumour DNA in urine to identify bladder cancer

Researchers from the University of Birmingham’s Bladder Cancer Research Centre have found a new way of detecting tumour DNA in urine to identify bladder cancer.